

Pavle Repovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1129137/publications.pdf>

Version: 2024-02-01

26
papers

1,014
citations

516215

16
h-index

580395

25
g-index

27
all docs

27
docs citations

27
times ranked

1651
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-6 (IL-6) Production by Astrocytes: Autocrine Regulation by IL-6 and the Soluble IL-6 Receptor. <i>Journal of Neuroscience</i> , 1999, 19, 5236-5244.	1.7	208
2	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 846-855.	13.9	201
3	Oncostatin M Regulation of Interleukin-6 Expression in Astrocytes. <i>Journal of Neurochemistry</i> , 2002, 75, 563-575.	2.1	68
4	Prostaglandin E ₂ is a Novel Inducer of Oncostatin-M Expression in Macrophages and Microglia. <i>Journal of Neuroscience</i> , 2002, 22, 5334-5343.	1.7	66
5	Fast Whole-Brain Three-dimensional Macromolecular Proton Fraction Mapping in Multiple Sclerosis. <i>Radiology</i> , 2015, 274, 210-220.	3.6	63
6	Oncostatin-M induction of vascular endothelial growth factor expression in astrogloma cells. <i>Oncogene</i> , 2003, 22, 8117-8124.	2.6	58
7	Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: Synergy with interleukin-1?, tumor necrosis factor-?, and bacterial lipopolysaccharide. <i>Glia</i> , 2003, 42, 433-446.	2.5	49
8	Optimization of glycolysis: A new look at the efficiency of energy coupling. <i>Biochemical Education</i> , 1997, 25, 204-205.	0.1	34
9	COVID-19 in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e783.	3.1	34
10	Optimization of glycolysis: new discussions. <i>Biochemical Education</i> , 1999, 27, 12-13.	0.1	29
11	Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. <i>Clinical Therapeutics</i> , 2018, 40, 2077-2087.	1.1	29
12	Treatment of Multiple Sclerosis Exacerbations. <i>Neurologic Clinics</i> , 2011, 29, 389-400.	0.8	28
13	Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction. <i>American Journal of Neuroradiology</i> , 2018, 39, 618-625.	1.2	27
14	Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e111-e120.	1.5	24
15	Management of Multiple Sclerosis Relapses. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 655-669.	0.4	22
16	Anion and Solvent Effects upon the Structures of Platinum(II) Complexes with Thiocrown Ligands: The Crystal Structures of [Pt(9S3)2](PF6)2·2 CH3NO2, [Pt(9S3)2](BF4)2·2 CH3NO2, [Pt(9S3)2](OTf)2·2 CH3NO2 and [Pt(18S6)](BF4)2. <i>European Journal of Inorganic Chemistry</i> , 2005, 2005, 479-485.		20
17	Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?. <i>European Journal of Neurology</i> , 2021, 28, 2115-2120.	1.7	12
18	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199399.	1.5	12

#	ARTICLE	IF	CITATIONS
19	Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 " Fatigue (MS) 8a. Multiple Sclerosis and Related Disorders, 2021, 54, 103117.	0.9	10
20	MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 561-572.	1.4	5
21	Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND. Neurology and Therapy, 2021, 10, 169-182.	1.4	4
22	Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Annals of Clinical and Translational Neurology, 2021, 8, 711-715.	1.7	4
23	The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Journal of Neurology, 2022, 269, 5319-5327.	1.8	4
24	The validity, responsiveness, and score interpretation of the PROMIS Physical Function " Multiple Sclerosis 15a short form in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103753.	0.9	2
25	Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. Multiple Sclerosis Journal, 2021, , 135245852110636.	1.4	1
26	Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19. Neurology and Therapy, 2022, , 1.	1.4	0